SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting

• Conditions: All Tumor Types

• Registration Number: NCT02834884
• Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Detailed Description

Patients are recruited in the platform for the research purpose of 4 downstream projects. For more information, please have a look at the "Groups and cohorts" section.

Study Timeline

• Study First Submitted: 2016-07-13
• Study First Submitted QC: 2016-07-13
• Study First Posted: 2016-07-15
• Study Start: 2017-05-03
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-29
• Last Update Posted: 2025-05-01
• Primary Completion: 2026-03
• Study Completion: 2026-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 4975

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To establish a quality assured platform to improve the understanding of tumor biology and cancer patients care	5 years	material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Secondary Outcome Measures

Name	Time	Method
To perform biospecimen and data based high quality research aiming to better understand the biology of cancer, and/or how it is currently managed and/or how to better diagnose and treat it in the future;	5 years
To investigate the effect of cancer treatment on the tumor, microenvironment and patients globally;	5 years
To collect large series of homogeneous clinical data to analyse the disease course and treatment performed;	5 years
To investigate the molecular pathways related to the development of specific tumors from a biological point of view;	5 years
To investigate the prevalence and validate the prognostic or predictive value of novel biomarkers in cancers;	5 years
To perform biospecimen and data based high quality research aiming to facilitate the discovery of new test for tumor biomarkers or facilitate the establishment of validated tests for tumor biomarkers;	5 years
To identify patients with molecular alterations in their tumor that can be matched to biomarker-driven clinical trials, to facilitate enrollment of cancer patients in biomarker-driven clinical trials.	5 years

Trial Locations

Locations (134)

Medical University Vienna - General Hospital AKH; 🇦🇹 Vienna, Austria

Onze Lieve Vrouw Ziekenhuis; 🇧🇪 Aalst, Belgium

ZAS Middelheim; 🇧🇪 Antwerp, Belgium

Hopitaux Universitaires - Institut Jules Bordet; 🇧🇪 Brussels, Belgium

Universitair Ziekenhuis Brussel; 🇧🇪 Brussels, Belgium

Cliniques Universitaires Saint-Luc; 🇧🇪 Brussels, Belgium

Universitair Ziekenhuis Gent; 🇧🇪 Gent, Belgium

Pole Hospitalier Jolimont - Hopital Jolimont; 🇧🇪 Haine-Saint-Paul, Belgium

U.Z. Leuven - Campus Gasthuisberg; 🇧🇪 Leuven, Belgium

C.H.U. Sart-Tilman; 🇧🇪 Liège, Belgium

Scroll for more (124 remaining)